Genesis Biopharma appoints new ceo and cfo

Anthony Cataldo and Michael Handelman also join board of directors

Genesis Biopharma, a US biotechnology company developing targeted cancer therapies, has named Anthony Cataldo as president and chief executive. He succeeds Robert Brooke, who is now a strategic advisor to the Manhattan Beach, California-based company.

In addition Genesis Biopharma has appointed Michael Handelman as chief financial officer, treasurer and secretary, succeeding Richard McKilligan.

Cataldo and Handelman have joined the company's Board, while Brooke, McKilligan and Mark Ahn have resigned as members.

‘I'm looking forward to working with the Genesis Biopharma board to further the progress of our important cancer technology, and to develop new strategic opportunities to build shareholder value,’ said Cataldo.

‘Genesis Biopharma's targeted anti-CD55 monoclonal antibody technology has widespread clinical utility, as it neutralises a key cancer defence mechanism that is over-expressed in more than 80% of tumours. It could provide a safe alternative to toxic chemotherapy regimens, and has the potential to expand and improve the clinical utility of already approved antibody therapies as well as some novel agents in development.’

Cataldo was formerly chairman, chief executive and a director of Oxis International. Prior to this he was non-executive co-chairman of the Board of MultiCell Technologies.

Handelman was chief financial officer of Oxis International. Prior to this he was cfo and coo of TechnoConcepts.

You may also like

Research & Development

Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research

Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development

PSI launches platform to speed up site ID, startup and enrolment in pivotal studies

SYNETIC is designed to speed up site identification, startup and patient enrollment in pivotal clinical trials
Ingredients

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery
Pharmaceutical

PharmNovo enhances its board ahead of Phase II development

The new board members bring complementary experience in drug development, clinical execution and partnering, supporting the company’s continued progress and dialogue with potential partners
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Research & Development

Baseline Therapuetics launches to advance GLP-1 Phase III Programme in Alcohol Use Disorder

The clinical-stage biotech has launched to progress BT-001, a once-weekly GLP-1 receptor agonist, into FDA-aligned Phase III trials for alcohol use disorder, with studies planned to begin in 2026
Research & Development

Researchers identify early signs of Parkinson's in the blood

Researchers at Chalmers University of Technology have identified early-stage Parkinson’s disease biomarkers detectable in blood, revealing a limited diagnostic window that could enable screening and earlier intervention years before motor symptoms appear
Subscribe now